Goldman Sachs Group downgraded shares of Intercept Pharmaceuticals (NASDAQ:ICPT) from a neutral rating to a sell rating in a report issued on Wednesday, Marketbeat Ratings reports.

Other analysts also recently issued research reports about the company. Wedbush reaffirmed a buy rating and set a $253.00 price objective on shares of Intercept Pharmaceuticals in a research note on Friday, December 22nd. Cowen reaffirmed a buy rating and set a $112.00 price objective on shares of Intercept Pharmaceuticals in a research note on Wednesday, November 1st. Oppenheimer reaffirmed a hold rating on shares of Intercept Pharmaceuticals in a research note on Tuesday, October 24th. Needham & Company LLC reaffirmed a hold rating on shares of Intercept Pharmaceuticals in a research note on Wednesday, November 1st. Finally, Citigroup set a $74.00 price objective on Intercept Pharmaceuticals and gave the stock a hold rating in a research note on Thursday, December 21st. Five investment analysts have rated the stock with a sell rating, ten have given a hold rating and ten have issued a buy rating to the company. The stock currently has an average rating of Hold and an average price target of $134.86.

Intercept Pharmaceuticals (NASDAQ ICPT) opened at $54.21 on Wednesday. The stock has a market capitalization of $1,337.69, a price-to-earnings ratio of -3.66 and a beta of -2.13. Intercept Pharmaceuticals has a 12-month low of $51.05 and a 12-month high of $135.59. The company has a debt-to-equity ratio of 3.15, a current ratio of 5.95 and a quick ratio of 5.95.

Several institutional investors and hedge funds have recently added to or reduced their stakes in ICPT. Senvest Management LLC acquired a new stake in shares of Intercept Pharmaceuticals in the 3rd quarter valued at about $33,883,000. First Trust Advisors LP raised its stake in shares of Intercept Pharmaceuticals by 101.5% in the 4th quarter. First Trust Advisors LP now owns 605,454 shares of the biopharmaceutical company’s stock valued at $35,371,000 after purchasing an additional 304,999 shares during the period. Emerald Advisers Inc. PA acquired a new stake in shares of Intercept Pharmaceuticals in the 4th quarter valued at about $9,497,000. Peregrine Capital Management LLC acquired a new stake in shares of Intercept Pharmaceuticals in the 4th quarter valued at about $7,055,000. Finally, Vanguard Group Inc. raised its stake in shares of Intercept Pharmaceuticals by 4.5% in the 2nd quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock valued at $160,797,000 after purchasing an additional 57,149 shares during the period. 74.37% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Intercept Pharmaceuticals (ICPT) Stock Rating Lowered by Goldman Sachs Group” was posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.watchlistnews.com/intercept-pharmaceuticals-icpt-stock-rating-lowered-by-goldman-sachs-group/1857789.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.